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Within an aging population, fracture incidences will rise and with the augmented risks
of impaired healing the overall risk of delayed bone regeneration will substantially
increase in elderly patients. Thus, new strategies to rescue fracture healing in the
elderly are highly warranted. Modulating the initial inflammatory phase toward a
reduced pro-inflammation launches new treatment options for delayed or impaired
healing specifically in the elderly. Here, we evaluated the capacity of the prostacyclin
analog Iloprost to modulate the inflammatory phase toward a pro-regenerative milieu
using in vitro as well as in vivo model systems. In vitro, Iloprost administration led
to a downregulation of potential unfavorable CD8+ cytotoxic T cells as well as
their pro-inflammatory cytokine secretion profile. Furthermore, Iloprost increased the
mineralization capacity of osteogenic induced mesenchymal stromal cells through both
direct as well as indirect cues. In an in vivo approach, Iloprost, embedded in a biphasic
fibrin scaffold, decreased the pro-inflammatory and simultaneously enhanced the anti-
inflammatory phase thereby improving bone healing outcome. Overall, our presented
data confirms a possible strategy to modulate the early inflammatory phase in aged
individuals toward a physiological healing by a downregulation of an excessive pro-
inflammation that otherwise would impair healing. Further confirmation in phase I/II trials,
however, is needed to validate the concept in a broader clinical evaluation.
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INTRODUCTION
Bone is one of the few tissues in the human body capable of regenerative, scar-free healing. Thus,
a bony injury can result in complete restoration of form and function, a restitutio ad integrum.
However, the complex bone healing process consisting of sequential, partly overlapping phases
is prone to failure (1–4). Even in today’s medical routine 5–10% of fracture patients suffer from
delayed healing or a resulting non-union (5–7). Therefore, impaired bone repair after injury is
still a clinically relevant problem, which will even further increase in the overall aging population
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(8). Thus, a better and deeper understanding of the underlying
biological mechanisms under unimpaired healing conditions is
necessary for the development of novel therapeutic treatment
strategies to improve unsuccessful bone regeneration.
The tight interaction of the immune system and bone
healing has been recognized in the emerging research field of
osteoimmunology. Especially the early phase of healing, the
inflammatory phase seems to be a promising target for immuno-
modulatory approaches to enhance bone healing (9, 10). The pro-
inflammatory reaction following injury (11) is an essential trigger
or initiator of the healing process. However, a pronounced or
prolonged pro-inflammatory reaction (due to a lack or damped
anti-inflammatory phase) will negatively impact the healing
process (12–14). Recently, specific subsets of the immune system
have been shown to negatively influence bone formation: Effector
and effector memory CD8+ T cells are producers of TNFα
(tumor necrosis factor alpha) and IFNγ (interferon gamma),
highly pro-inflammatory cytokines which have been found to
deter osteogenic differentiation (15). Therefore, downregulation
of the negative influence of immune cell subsets could potentially
enhance bone healing. Anti-inflammatory cytokines such as
interleukin (IL) 4/IL-13 further the M2/Th2 response, thus
promoting the immune response triggered by tissue injury under
a regulatory phenotype rather than a M1/Th1 pro-inflammatory
phenotype. A proof of concept study showed that applying
IL-4/IL-13 during the initial bone healing phase could indeed
enhance bone formation (16). However, a distinct initiation of
an anti-inflammation has not been evaluated so far.
Within this study, a prostacyclin (PGI2) analog was tested
as a possible immune modulatory drug to enhance bone
formation. PGI2 is a small molecule derived from arachidonic
acid by cyclooxygenase-2 (Cox-2) and prostacyclin synthase.
Endogenous PGI2 is already well-known playing an important
role in cardiovascular diseases due its vasodilatory function
(17, 18). In recent years, a potential role of PGI2 as
immune modulatory agent was detected by promoting an
anti-inflammatory and immunosuppressive effect (19, 20). In
particular, the PGI2 receptor (IP) is present on platelets,
medullary thymocytes, neutrophils, dendritic cells, eosinophils,
T regulatory cells, and activated T cells (21, 22). Thus, PGI2
has an impact on both, cells of the innate, and of the adaptive
immunity. Due to the strong interconnectivity of the immune
system and the skeletal system during bone regeneration, PGI2
could represent a potential and promising agent to further bone
fracture healing. In the context of bone injuries, the PGI2 analog
Iloprost was already successfully used to treat bone marrow
edema and avascular necrosis (23, 24). However, the effect of
PGI2 on the process of bone formation/regeneration was not
analyzed by any study so far. In the here presented study,
we investigated the immune modulatory effect of PGI2 in the
context of bone regeneration. Since the half-life of endogenous
PGI2 is very short, the PGI2 analog Iloprost was used. Iloprost
is approved as treatment for pulmonary arterial hypertension
(25) and peripheral arterial occlusive disease (26), respectively.
Within the here presented study, we focused on the immune
suppressive capacities of Iloprost, especially on CD8+ T cells and
macrophages. Immune modulatory properties were confirmed
and the postulated positive osteogenic effect was verified in vitro.
In a final proof of concept in vivo trial, the positive impact of an
application of Iloprost during the early bone healing phase was
demonstrated in a mouse osteotomy model.
MATERIALS AND METHODS
Animal Model
Female C57BL/6N (Charles River Laboratories, Wilmington,
MA, USA) were used for the analysis of the bone healing
capacity in vivo. All mice were purchased at an age of 8
weeks and mice were housed in small groups in our animal
facility. Animals were kept for at least 4 weeks in the non-
SPF area of the animal facility (area in the animal facility
without filtered air supply for the cages and without additional
barrier) to allow a higher environmental pathogen exposure to
challenge and tomoderately activate the adaptive immune system
of the animals. All mice experiments were carried out with
the ethical permission according to the principles and policies
established by the Animal Welfare Act, the National Institutes
of Health Guide for Care and Use of Laboratory Animals, and
the National Animal Welfare Guidelines. All animal experiments
were approved by the local legal representative animal rights
protection authorities (Landesamt for Gesundheit und Soziales
Berlin: G0008/12; T0119/14; T0249/11). All results are reported
according the ARRIVE guidelines.
Sample Harvesting for the in vitro Analysis
With Immune Cells
For the immunomodulatory analysis in vitro, femora, and humeri
were harvested from C57BL/6N mice. To isolate the bone
marrow, the epiphyses were cut off from the bones and the
bone marrow was flashed out into RPMI 1640 media (Biochrom,
Berlin, Germany). The bone marrow was pushed through a
40µm cell strainer to get a single cell suspension. Residing
erythrocytes were lysed for 4min at room temperature (RT) in
ACK lysing buffer (Gibco Life Technologies GmbH, Darmstadt,
Germany). After centrifugation, cells were resuspended in 10ml
RPMI 1640 media and counted.
Isolation of CD8+ T Cells
CD8+ T cells were isolated from bones harvested from
C57BL/6N mice. The isolation was performed via the CD8
S-pluriBeads anti-ms kit (pluriSelect Life Sciences, Leipzig,
Germany). The isolation was carried out following the
manufacturer’s instructions. Briefly, complete bone marrow
cells were resuspended in a 1:2 mixture of the isolation and
wash buffer and 40 µl S-pluriBeads were added per 1 x 106
target cells and the mixture was incubated for 30min at RT
while continuous slowly shaking (horizontal roller mixer). Cell
mixture was washed trough a S-pluriStrainer and target cells
remained on the S-pluriStrainer. To detach the CD8+ T cells
from the S-pluriBeads, detachment activation buffer D was
added to the cells. Detached isolated cells were collected in a new
tube, washed, and counted.
The purity of the isolated CD8+ T cells was confirmed by
flow cytometry. The following antibodies were used: Life/Dead,
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α-CD3 PerCP, α-CD4 AF700, and α-CD8 eF450. The incubation
with the antibodies was done on ice for 20min. After the staining,
cells were washed, fixed, and analyzed with a flow cytometer LSR
II (Becton Dickinson Bioscience, Heidelberg, Germany).
Study Design for the in vitro Analysis of the
Osteogenic and Osteoimmunological
Effect of Iloprost
The objective of this study was to investigate the potential of
the prostacyclin analoque Iloprost to improve bone healing. For
this analysis, the osteogenic and osteoimmunological effect of
Iloprost was first evaluated in vitro. Subsequently, Iloprost was
inserted into a fibrin clot in order to confirm the pro-osteogenic
potential of Iloprost in an in vivo proof of concept approach
in a mouse osteotomy model. For the in vitro analysis, Iloprost
was directly added to the osteogenic differentiation culture of
bone marrow mesenchymal stromal cells (BM MSCs) isolated
from the femur of C57BL/6Nmice (Figure 1, left). To investigate
an indirect effect of Iloprost on the mineralization capacity of
osteogenic induced BM MSCs, all bone marrow cells or isolated
CD8+ T cells from the bone marrow were stimulated with α-
CD3/α-CD28 and the obtained conditioned media were added
to the osteogenic differentiation culture of BM MSCs (Figure 1,
right). The osteogenic differentiation was quantified based on
mineralization by Alizarin Red staining.
Cell Stimulation for the Production of
Conditioned Media
Bone marrow and isolated CD8+ T cells were stimulated by
an α-CD3/α-CD28 stimulation for 2 days in 96 well-plates. The
stimulation was performed in RPMI 1640 media supplemented
with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
(P/S), 50µM β-mercaptoethanol, and 10 ng/ml IL-2. In the
respective experimental setup, either PBS or 300 nM or 3µM
Iloprost were added to the culture. 5 x 105 cells in 225 µl were
plated per well of a 96 well-plate. After the two stimulations,
the supernatant was harvested (conditioned media) and stored
at−80C.
Isolation and Polarization of Macrophages
1 x 106 isolated bone marrow cells were plated per well into
a 96 well-plate and incubated for 3 days in RPMI complete
media: RPMI 1640 supplemented with 50 ng/ml macrophage
colony-stimulating factor (M-CSF), 1% P/S, 10% FBS, and 50µM
β-mercaptoethanol. Subsequently, RPMI complete media was
replaced by the respective polarization media and cells were
polarized for additional 3 days. For M8: RPMI complete media
with PBS; M1: RPMI complete media with 20 ng/ml IFNγ and
M2: 20 ng/ml IL-4/IL-13. The produced conditioned media was
harvested and stored at −80◦C. Macrophage monolayers were
washed twice with PBS and fixed with 4% PFA/PBS for 10min.
Storage was done in PBS at 4◦C for subsequent confirmation of
polarization via immunofluorescence.
Immunofluorescence Staining of Polarized
Macrophage Subsets
The immunofluorescence staining of polarized macrophages
were realized on fixed cellular macrophage monolayers. Cells
were shortly washed with PBS, permeabilized in 100 µl PBS
supplemented with 0.1% Tween for 30min and subsequently
blocked for 30min with PBS supplemented with 5% FBS. The
following antibodies were used for the staining: α-CD68 FITC,
α-CD206 PE, and α-CD80 AF647. Antibodies were incubated
for 1 h in the dark at RT. Cells were washed with PBS and cell
nuclei were stained with DAPI for 10min in the dark at RT. Cell
monolayers were washed twice with PBS and wells were kept at
4◦C in the dark until imaging. Imaging was performed with a
standard fluorescence microscope (Axio Observer, Carl Zeiss).
Investigation of the Immunomodulatory
Effect of Iloprost
To investigate the immunomodulatory effect of Iloprost on
immune cells, ELISA were performed analyzing the secretion
of IFNγ, TNFα, and IL-10 as indicated. Frozen conditioned
media were thawed and analyzed with respective ELISA kits
following the manufacturer’s protocol. ELISA was performed
with a Mouse IFNγ ELISA Ready-SET-Go! R©, Mouse TNFα
ELISA Ready-SET-Go! R©, and Mouse IL-10 ELISA Ready-SET-
Go! R© from eBioscience (Affymetrix, Santa Clara, CA USA).
The samples were incubated at 4◦C overnight. Final staining
reactions were stopped with 1M H3PO4 and absorbance values
were acquired at 450 nm with a reference wavelength of
570 nm with Tecan Infinite M200 PRO (Tecan, Männedorf,
Switzerland) and analyzed with i-control 1.9 software (Tecan,
Männedorf, Switzerland).
Isolation and Cultivation of Mesenchymal
Stromal Cells
At least 3 x 107 isolated bone marrow cells were cultured
in expansion media: low glucose DMEM media supplemented
with 10% FBS, 1% P/S, and 1% glutamax. Media exchange was
performed twice a week to remove non-adherent cells until
cultures were confluent. To detach the MSC monolayers, cells
were washed once with PBS. TrypLE was added to the monolayer,
incubated for 5min at 37◦C. The cell suspension was washed,
centrifuged and the passaged cells were plated with increasing
surface area.
Osteogenic Differentiation of MSCs and
Quantification by Alizarin Red Staining
1.5 x 104 MSCs were seeded per well into a 96 well-plate. Cells
were cultured in expansion media for 2 days. Subsequently,
osteoinductivemedia was applied to the cells: low glucose DMEM
media supplemented with 10% FBS, 100 nM dexamethasone,
10mM β-glycerol phosphate, 50µM L-ascorbate-2-phosphate,
1% P/S, and 1% glutamax. Osteogenic differentiation was stopped
after 14 days including a media exchange every 3–4 days. When
conditioned media of stimulated bone marrow or CD8+ T cells
was supplemented, double concentrated osteoinductive media
was mixed 1:2 with the respective conditioned media.
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FIGURE 1 | Methodological scheme for the in vitro analysis of the osteogenic effect and osteoimmunological effect of Iloprost. BM MSC, bone marrow mesenchymal
stromal cells; BM cells ,bone marrow cells; CM, conditioned media.
Alizarin Red staining was applied to quantify the osteogenic
differentiation of the cultured MSCs. After a 14 days culture
in osteoinductive media, well-plates were washed twice with
PBS. Cell layers were fixed for 10min at RT in 50 µl 4%
paraformaldehyde/PBS (PFA/PBS). Cell nuclei were stained for
DAPI for 10min in the dark at RT. Cells were washed in
ddH2O and incubated with 0.5% Alizarin Red for 10min at RT.
Cells were washed five times with ddH2O and cell layers were
dried before imaging. For the quantification, Alizarin Red was
detached with 10% cetylpyridinium chloride for 30min at RT and
optical density was measured and quantified with the plate reader
Infinite M200 PRO (Tecan, Männedorf, Switzerland).
Chondrogenic Differentiation of MSCs and
Quantification by Histomorphometry
3 x 105 MSCs were transferred into a 15ml tube for the
chondrogenic differentiation. Cells were centrifuged and
chondrogenic induction media was carefully added to the
cells without resuspension: high glucose DMEM media
supplemented with 100 nM dexamethasone, 50µg/ml L-
ascorbate-2-phosphate, 350µM L-proline, 2mM sodium
pyruvate, 6.25µg/ml Insulin-transferrin-sodium selenite media
supplement, 1.25 mg/ml bovine serum albumin, 5.35µg/ml
linoleic acid, 10 ng/ml TGF-β1, 10 ng/ml BMP-2, 1% P/S, and
1% glutamax. Pellets were cultured for 21 days under hypoxic
conditions. Chondrogenic inductive media was changed twice
a week.
For quantification, chondrogenic differentiated cell pellets
were paraffin embedded, cut and stained with Alcian Blue
(staining of the proteoglycans). Therefore, cell pellets were fixed
for 2 h in 4% PFA/PBS, washed twice in PBS and dehydrated in an
increasing alcohol series: 30 s in 70% EtOH, 20min in 80% EtOH,
20min 96% EtOH and twice 20min in 100% EtOH. Cell pellets
were incubated for 15min in Xylol and subsequently paraffin
embedded. Four micrometer thick sections were cut from three
different areas of each pellet. Deparaffinized sections (incubation
of the sections twice in Xylol for 10min each and in a descending
alcohol series) were washed in ddH2O for 2min, equilibrated in
3% acetic acid for 3min, stained in 1% Alcian Blue for 45min,
washed in 3% acetic acid, washed in ddH2O, and stained for
cell nuclei in Nuclear Fast Red for 2min. Pellets were shortly
washed in ddH2O and 70% EtOH. After an ascending alcohol
series, pellets were incubated twice in Xylol, 10min each, and
embedded. Acquired images were quantified based on the blue
values of bright field images.
Investigation of the Cellular Metabolic
Activity by Prestoblue
Using the PrestoBlue Cell Viability Reagent (Thermo Fisher
Scientific, Waltham, MA, USA), the metabolic activity of the
stimulated cells was investigated after manufacturer’s protocol.
The reagent was diluted in RPMI complete media (for bone
marrow cells) or low glucose DMEM (for MSCs), respectively,
and applied to the cultured cells. After a 1 h incubation, the
supernatant was collected and fluorescence top reading was
performed at 560 nm excitation and 590 nm emission with the
plate reader. For background correction, fluorescence values of
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no-cell control wells, which contained only reagent solution were
averaged and subtracted from values of experimental wells.
Setting of an Osteotomy for the in
vivo Analysis
The pro-regenerative potential of Iloprost was evaluated in a
mouse osteotomy model. Therefore, mice were anesthetised by
inhalation of Isoflurane. Before surgery, the animals received
subcutaneous injection of the analgesic Buprenorphine (0.03
mg/kg s.c.) and of the antibiotic Clindamycin (0.02ml s.c.). The
operation area of the left femur was shaved and disinfected. The
skin was opened by a longitudinal cut from the knee to the hip.
The femur was bluntly exposed and stabilized by an external
fixator (MouseExFix, RISystem AG, Davos, Switzerland). An
osteotomy of 0.7mm was introduced between the middle pins
using a Gigli wire saw (RISystem AG, Davos, Switzerland). A
biphasic fibrin clot (loaded with either 3µM Iloprost or PBS)
(Tissucol-kit Immuno, Baxter) was inserted into the osteotomy
gap. The skin was closed and sutured. Mice were brought back
to the cage and observed until they were fully mobile again. As
post-operative analgesia, Tramadol hydrochloride (0.1 mg/ml)
was added to the drinking water for 3 days.
Micro-Computed Tomography of
Osteotomized Mouse Bones
To evaluate the healing outcome after Iloprost administration,
fractured femora were harvested 21 days post-osteotomy
and analyzed by µCT. Therefore, mice were euthanized by
administering ketamine and xylazine (i.p., ketamine: 120 mg/kg,
xylazine: 16 mg/kg) and cervical dislocation in deep anesthesia.
After preparation of the femora, they were directly fixed in
4% PFA/PBS for 4 h at 4◦C. Subsequently, the bones were
dehydrated in an ascending sugar series: 10, 20, and 30%, for
24 h for each at 4◦C. The bones were scanned in a µCT Viva
40 (SCANCO Medical AG, Brüttisellen, Switzerland). For the
scan, the following parameters were used: 10.5µm voxel size,
55keVp, and 145 uA. A gray value threshold was defined before
analysis in order to be able to distinguish between mineralized
and non-mineralized bone tissue (27). The global threshold for
defining mineralized bone was set to 242, which corresponds
to a mineralization of 369.9mg hydroxyapatite (HA)/cm2. The
scanned volume of interest (VOI) included 190 slices around the
middle of the fracture gap to the distal and proximal part of
the femur, respectively. For the quantification of the µCT data,
cortical bone was excluded from newly formedmineralized bone.
Histological and
Immunohistological Analysis
For histological and immunohistological analysis, fractured
bones were cryo embedded. Seven micrometer thick sections
were cut and stained either for Movat’s Pentachrome (overview
staining) or the following cell types (immunofluorescence
staining): CD4+ and CD8+ T cells, IFNγ-producing
CD8+ T cells, osteoblasts, osteoclasts and differentially
polarized macrophages.
The Movat pentachrome staining was done as follows: cryo-
sections were thawed for 1 h at RT and fixed for 10min in
4% PFA/PBS. Sections were washed twice in PBS/Tween-20
for 5min. Subsequently, sections were incubated for 3min in
3% acetic acid, for 30min in 1% Alcian Blue/3% acetic acid,
and differentiated for 5min in 3% acetic acid. After washing
in ddH2O, sections were incubated for 1 h in ethyl alcohol,
washed twice in tap water, shortly in ddH2O and stained in iron
hematoxylin (after Weigert) for 10min. After washing with tap
water, sections were incubated for 15min in brilliant crocein-
acid fuchsine. Tissue slides was shortly placed in 0.5% acidic
acid, followed by a 20min incubation in 5% phosphotungstic
acid. After 1min in 0.5% acetic acid, slides were incubated 3x à
5min in 96% EtOH and stained with Saffron-du-Gatinais for 1 h.
Subsequently, they were washed again 3x in 96% EtOH for 2min
each, 2x in Xylol for 10min each and embedded.
Analysis of the immune cell subsets and osteoblasts,
osteoclasts was done by immunofluorescence staining. All steps
were performed at RT in a humidified chamber. Thawed cryo-
sections were fixed for 20min in 4% PFA/PBS/Tween-20 and
washed twice with PBS/Tween-20. Sections were blocked in 1x
TBS supplemented with 7% FBS and 0.05% Tween-20 for 1 h.
Blocking buffer was decanted and the primary antibodies were
applied to the respective section in the following combinations:
(1) CD4+ and CD8+ T cells and osteoblasts: CD4 AF594, CD8
PE, osteocalcin; (2) IFNγ-producing CD8+ T cells: CD8 PE and
IFNγ; and (3) differentially polarized macrophages: CD68 FITC,
CD206 PE, and CD80 AF647. Tissue sections were washed in
1x TBS and, if necessary, incubated for 2 h with a secondary
antibody: anti-rabbit AF647 for osteocalcin or anti-rat AF594
for IFNγ and for CD4. For the staining of osteoclasts, antigen
retrieval was performed with ProteinaseK for 15min on thawed
cryo-sections. Sections were washed PBS/Tween-20 and fixed
as described above. After washing and blocking, sections were
stained for cathepsinK in 3.5% FBS, 0.025% Tween in tris-
buffered saline (TBS) for 2 h. Sections were washed and stained
for CD68 (FITC) and the secondary antibody for cathepsinK
anti-rabbit AF647 in 3.5% FBS, 0.025% Tween in TBS for 2 h.
Sections were washed, stained for cell nuclei with DAPI for
10min and subsequently embedded. Sections were analyzed
with a laser scanning microscope LSM 710 (Carl Zeiss AG,
Oberkochen, Germany).
Statistics
The statistical evaluation of the presented data was done with
the programs Graph Pad Prism and SPSS. Data were presented
as dot plot graphs. Statistics were done by using the Mann-
Whitney U test and data were statistically significant if p ≤ 0.05.
For comparison of more than two study groups the Bonferroni’s
post-hoc test was used.
RESULTS
Immunomodulatory Effects of Iloprost on
Immune Cells
We first tested the immunomodulatory properties of Iloprost on
murine immune and mesenchymal stromal cells (MSCs) in vitro.
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Both, immune cells and MSCs are known to be essential for the
early healing phase in bone regeneration.
In a first attempt, two different concentrations of Iloprost
were tested on the whole bone marrow cellular composition:
300 nM and 3µM. As readout, the secretion of the pro-
inflammatory cytokines IFNγ and TNFα was analyzed. Both
cytokines play an important role as signaling molecules in bone
repair, especially in the early fracture healing phase. However,
too high amounts of them negatively affect bone repair by
diminishing the formation of mineralized matrix by MSCs
(15). After a 2-day stimulation of the cells by the different
concentrations of Iloprost, the concentration of secreted IFNγ
and TNFα was significantly decreased in comparison to the
control (PBS supplementation) (IFNγ: ∼130 to ∼55 ng/ml;
TNFα: ∼65 to ∼40 pg/ml) (Figures 2A,B). Comparing the
two different concentrations of Iloprost, the supplementation
of the higher one (3µM) led to an even more pronounced
decrease of the secreted cytokines. As expected, non-activated
cells showed almost no secretion of IFNγ and TNFα. The
metabolic activity of the stimulated bone marrow cells was also
downregulated by the supplementation of Iloprost in comparison
to the control (Figure 2C).
In patients, we already showed that a too high amount of
CD8+ T cells, one special subset of the adaptive immunity,
negatively regulates successful bone repair (15). CD8+ T cells
are one of the main producer of pro-inflammatory cytokines
in the early bone repair phase. Therefore, as a next step, we
evaluated the immunomodulatory effect of Iloprost on murine
CD8+ T cells. CD8+ T cells were isolated via PluriBeads
(pluriSelect) from bone marrow and spleen. The purity of the
isolated cells was confirmed by flow cytometry after separation
as well as after the duration of the in vitro stimulation and stayed
above 80% (Figure 3A). Similar to the stimulation of the whole
bone marrow cellular fraction, isolated CD8+ T cells showed
a decreased secretion of IFNγ and TNFα under the presence
of 3µM Iloprost in comparison to the control (IFNγ: ∼410
to ∼250 ng/ml; TNFα: ∼275 to ∼180 pg/ml) (Figures 3B,C).
The metabolic activity was again slightly downregulated by
the Iloprost supplementation (Figure S1).
Besides cells of the adaptive immunity, also cellular
compartments of the innate immune system play a key role
in the early fracture healing phase. Macrophages are one of
the first cells infiltrating the fracture area and are necessary
for (a) the clearance of the cell debris as well as for (b) the
recruitment of further cells important for the progression of the
healing cascade due to their secreted cytokine profile (16, 28).
We already demonstrated the importance of macrophages in
bone regeneration using an in vivo mouse osteotomy model.
After a chemically induced reduction of the macrophage cell
population, a disturbed bone healing outcome was observed
in comparison to the control group while an induction of
the regulatory M2 macrophage phenotype (addition of IL-
4/IL-13) lead to a significantly enhanced healing outcome
(16). In the here presented study, we further tested whether
the supplementation of Iloprost promotes simultaneously the
downregulation of pro-inflammatory and the upregulation
of anti-inflammatory cytokines by M8, M1, or M2 polarized
macrophages, respectively (Figure 4). Regarding the secretion
of TNFα, the supplementation of Iloprost led to a decreased
secretion by MΦ as well as by pro-inflammatory M1 (∼50
to ∼20 pg/ml) (Figure 4A). Whereas, the secretion of the
anti-inflammatory cytokine IL-10 was significantly upregulated
in the M2 type, but unaffected in the M8 and M1 macrophages
(∼290 to∼410 pg/ml) (Figure 4B). The polarization culture was
confirmed by immune fluorescence staining of the stimulated
and polarized cells (Figure 4C). M8 macrophages were
identified by the marker expression CD68 (green fluorescence
signal). M1 were double positive for CD68 and CD80 (CD80:
white fluorescence signal) and M2 double positive for CD68
and CD206 (CD206: red fluorescence signal). Cell nuclei were
identified by DAPI (blue fluorescence signal).
Effects of Iloprost on the Osteogenic and
Chondrogenic Differentiation Capacity of
Mesenchymal Stromal Cells
MSCs are the precursor cells for cartilage producing
chondrocytes and bone forming osteoblasts. During secondary
bone healing, a cartilage template is first build. These
chondrocytes further get hypertrophic, mineralize and are
subsequently replaced by newly formed woven bone produced
by osteoblasts. Thus, a cartilage template is indispensable for
successful bone regeneration. Therefore, the osteogenic and
chondrogenic differentiation capacity of MSCs was investigated
under the influence of Iloprost. We tested again two different
concentrations of Iloprost: 300 nM and 3µM, respectively.
For the osteogenic differentiation, monolayers of MSCs
cultured for 14 days in osteoinductive media were stained with
Alizarin Red to reveal the calcification of the cells (Figure 5).
The quantification of the Alizarin Red staining demonstrated
that Iloprost had no negative effect on the osteogenic capacity
of MSCs (Figures 5A,B). The metabolic activity as well as the
cell number of the cultured MSCs were also unaffected by the
presence of Iloprost in the osteoinductive media (Figures 5C,D).
After the demonstration that Iloprost is not affecting the
mineralization capacity of MSCs, we evaluated the impact of
Iloprost on their capacity to differentiate into the chondrogenic
cell lineage. Representative images of Alcian Blue stained paraffin
sections of cartilage pellets are presented in Figure 6A. The
quantification of the Alcian Blue staining revealed no negative
effect on the proteoglycan production of chondrogenically
induced MSC pellets under the supplementation of Iloprost in
comparison to the PBS control (Figure 6B).
Osteoimmunological Effect of Iloprost
In the first part of the study, we demonstrated that the
supplementation of Iloprost promotes the functionality of
immune cells toward both, a reduction of pro-inflammatory
signals and an induction of anti-inflammatory ones. We further
showed that Iloprost had no negative effect on the osteogenic as
well as chondrogenic differentiation capacity of MSCs. Next, we
wondered, whether the immune modulatory effect of Iloprost on
immune cells is also influencing the osteogenic capacity of MSCs.
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FIGURE 2 | Immunomodulatory effects of Iloprost on bone marrow cells. Bone marrow cells were stimulated for 2 days by α-CD3/α-CD28 in addition to either PBS or
two different concentrations of Iloprost (300 nM or 3µM, respectively). The following secreted cytokine concentrations were evaluated: IFNγ (A) and TNFα (B). The
metabolic activity of the stimulated bone marrow cells was measured via Prestoblue (C). n = 6.
FIGURE 3 | Immunomodulatory effects of Iloprost on isolated CD8+ T cells. The purity of the isolated CD8+ T cells after bead-based separation as well as after
in vitro stimulation was confirmed by flow cytometry (A). CD8+ T cells were stimulated by α-CD3/α-CD28 in addition to either PBS or 3µM Iloprost. The following
secreted cytokine concentrations were evaluated: TNFα (B) and IFNγ (C); n = 6.
Therefore, conditioned media (CM) of α-CD3/α-CD28
stimulated and Iloprost treated bone marrow cells and
isolated CD8+ T cells, respectively, were added to the
osteoinductive culture of MSCs. The CM of activated bone
marrow cells significantly decreased the mineralization
capacity of MSCs in comparison to the control (cultivated
MSCs in osteoinductive media, OM) (Figures 7A,B). The
supplementation of Iloprost during the α-CD3/α-CD28
stimulation of bone marrow cells was able to compensate
partially the negative impact on mineralization induced by
the activation (Iloprost, activated). CM of non-activated bone
marrow cells had no effect on the mineralization capacity of
MSCs (PBS, non-activated).
Repeating the analysis of the osteoimmunological effect
of Iloprost on MSCs with isolated CD8+ T cells, similar
results were obtained. CM of activated CD8+ T cells led
to a significant decrease of mineralized matrix synthesis of
cultured MSCs compared to the control (MSCs cultured in
OM) (Figures 8A,B). Again, the supplementation of Iloprost
to the stimulation of CD8+ T cells significantly improved
the osteogenic matrix production by MSCs (Figures 8A,B;
Iloprost, activated). However, this was still significantly lower
in comparison to the OM control. CM of non-activated
CD8+ T cells had no effect on the mineralization of MSCs
(PBS, non-activated).
Summarizing the data from our in vitro study, we confirmed
the immune modulatory effect of Iloprost on the secreted
cytokine profile of immune cells. We also showed that Iloprost
had no effect on the cartilage and bone forming capacity
of MSCs. Thus, Iloprost is not negatively affecting the pro-
regenerative functionality of MSCs. In a next step, we tested
the capacity of Iloprost as a bone healing promoting agent
in our mouse osteotomy model in a proof of concept
in vivo approach.
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FIGURE 4 | Immunomodulatory effects of Iloprost on polarized bone marrow macrophages. Macrophages were polarized for 3 days toward the M1 or M2 type,
supplemented with either PBS or 3µM Iloprost. (A,B) The following secreted cytokine concentrations were evaluated: TNFα (A) and IL-10 (B) of M1-type induced and
M2-type induced polarized macrophages, respectively. (C) Representative immune fluorescence images of unpolarised CD68+ M8 macrophages (on top),
CD68+CD80+ M1 macrophages (middle), and CD68+CD206+ M2 macrophages (bottom). Color code of the immune fluorescence images: CD68 = green, CD80 =
white, CD206 = red, and cell nuclei = blue (DAPI). Scale bars: 100µm; n = 6.
Iloprost–A Potent Agent to Promote Bone
Fracture Healing in vivo?
In bone regeneration, a first pro-inflammatory phase is
indispensable for the initiation of the healing cascade. Due to
the anti-inflammatory effect of Iloprost via its effect on immune
cell function shown in vitro, we chose an application strategy,
where the applied Iloprost will be successively released from
a biphasic fibrin scaffold, thus allowing the pro-inflammatory
phase to proceed. Fibrous tissue is a component of the classical
healing cascade in bone regeneration and thus represents an
endogenous material, which is already present in the fracture
gap. Furthermore, fibrin is biocompatible and biodegradable.
Iloprost embedded in a fibrin clot was inserted during surgery
in the osteotomy gap. Due to the biphasic structure of the fibrin
scaffold, the included Iloprost would not be directly released in
the fracture zone at the onset of the surgery but with a delay. This
delay allows the initial pro-inflammatory phase to proceed and to
initiate the healing cascade.
The healing outcome was evaluated 21 days post-surgery. The
model was chosen to enable detection of healing enhancement–
with a gap size of 0.7mm the healing is not concluded
after 21 days (control) (Figure 9, PBS). Regarding the Iloprost
treated group, µCT analysis 21 days post-surgery showed an
improved healing outcome of the mice receiving Iloprost in
comparison to the control group (mice with fibrin scaffold,
PBS supplementation) (Figure 9; Iloprost: mice with Iloprost
supplementation; PBS: control group). The quantification of the
µCT data confirmed the already visually seen improved healing
by a significant increase of bone volume, total callus volume
and the ratio of bone volume/total callus volume in the Iloprost
treated animals with regard to the control (Figures 9B–D).
Next to the µCT evaluation, histological and
immunohistological analyses were performed on cryosections
of the fractured femora 3 days and 21 days post-osteotomy
(Figures 10, 11). Movat Pentachrome staining was performed
to evaluate the relative amount of mineralized bone, cartilage,
connective tissue and bone marrow (Figure 10). In Figure 10A,
representative Movat Pentachrome pictures are presented to
illustrate the tissue formation in and around the osteotomy
gap at the respective time point. Three days post-surgery, the
fibrin scaffold was still visible within the osteotomy gap in
both groups, the control (PBS) and Iloprost treated animals
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FIGURE 5 | Effect of Iloprost on mineralization capacity of osteogenically induced MSCs. Monolayers of MSCs were stained with Alizarin Red to visualize the
formation of mineralized matrix. (A,B) Representative images of the Alizarin Red staining of cultured MSCs with osteoinductive media after 14 days of cultivation.
Different concentrations of Iloprost were supplemented to the osteoinductive media (300 nM and 3µM, respectively) (A). Quantification of the Alizarin Red staining (B).
The metabolic activity of the cultured MSCs was measured by Prestoblue (C). Determination of the cell number of the cultured MSCs under the different stimuli (D).
Scale bars: 200µm; n = 6.
FIGURE 6 | Effect of Iloprost on cartilage formation capacity of chondrogenically induced MSCs. (A) Alcian Blue stained paraffin sections of cartilage pellets after 21
days of incubation in chondroinductive media, supplemented with different concentration of Iloprost (300 nM and 3µM, respectively) or PBS as control.
(B) Quantification of the Alcian Blue staining. Scale bars: 200µm; n = 6.
(Iloprost), indicated by a red color after Movat’s Pentachrome
staining (Figure 10A, left). After 21 days, no fibrin scaffold
was detected anymore in or around the osteotomy area
(Figure 10A, right). Histomorphometrical analysis of the
tissue distribution revealed a significantly higher amount of
mineralized bone and cartilage tissue 21 days post-surgery in
the Iloprost treated group in comparison to the control animals
(Figure 10B). Three days post-osteotomy, both groups showed
almost no proportion of mineralized bone or cartilage tissue.
Both groups showed just slightly differences in the amount of
connective tissue at both investigated time points (Figure 10D,
connective tissue). Regarding the area of bone marrow, the
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FIGURE 7 | Osteoimmunological effect of Iloprost treated bone marrow cells. α-CD3/α-CD28 activated bone marrow cells were cultured either with Iloprost or PBS as
control. Obtained conditioned media was added to an osteogenic differentiation culture of MSCs and the secretion of mineralized matrix was measured by Alizarin
Red staining. (A) Representative images of the Alizarin Red staining of the different culture conditions. (B) Quantification of the Alizarin Red signal. OM, osteoinductive
media. Scale bars: 200µm; n = 6.
FIGURE 8 | Osteoimmunological effect of Iloprost treated isolated CD8+ T cells. Isolated α-CD3/α-CD28 activate CD8+ T cells were cultured either with Iloprost or
PBS as control. Obtained conditioned media was added to an osteogenic differentiation culture of MSCs and the secretion of mineralized matrix was measured by
Alizarin Red staining. (A) Representative images of the Alizarin Red staining of the different culture conditions. (B) Quantification of the Alizarin Red signal. OM,
osteoinductive media. Scale bars: 200µm; n = 6.
Iloprost treated mice displayed a slightly higher amount 21 days
after surgery.
To better understand the impact and direct influence
of Iloprost during the early phase of bone healing,
immunohistochemical (IHC) analyses were performed on
bone sections of mice sacrificed 3 days post-osteotomy. At
this time point, Iloprost conducted its immune modulatory
effect as shown below (Figure 9). In addition, around 3 days
post-osteotomy, the starting shift of the pro-inflammatory into
the anti-inflammatory phase is observed in our chosen mouse
osteotomy model system.
First, the distribution of CD4+ and CD8+ T cells (identified
by CD4 and CD8, respectively), as well as osteoblasts (identified
by osteocalcin, OCN) was investigated in a defined region of
interest (ROI) in and around the fracture zone (Figures 11A,B).
Quantification of the analyzed bone sections revealed a
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FIGURE 9 | Proof of concept approach of Iloprost to improve bone fracture healing in vivo. µCT analysis of the healing outcome 21 days post-osteotomy in a mouse
osteotomy model. (A) Representative µCT images of the Iloprost treated (right) and control (left, PBS) group. The upper row shows the 3D reconstruction of the µCT
measurement. In the lower row, 3D reconstruction was cut in the middle to evaluate the healing progression. The color code indicates the mineralization state,
increasing from blue to red. (B–D) Quantification of the µCT results; n = 6.
significantly reduction of the relative amount of CD4+ and
CD8+ T cells in the Iloprost treated mice in comparison
to the control. The relative number of osteoblasts was not
affected by Iloprost treatment. Next, we were interested in the
IFNγ producing CD8+ T cells, which were already shown to
be detrimental for successful bone repair. Iloprost treatment
led to a clear decrease of IFNγ producing CD8+ T cells
with regard to the control group (Figure 11C, highlighted by
arrows). Next to the T cells, the distribution of M8, M1,
and M2 type macrophages was also evaluated 3 days post-
osteotomy. Corresponding to the chosen marker set for the in
vitro analysis, CD68 was used as pan-macrophage marker, CD68
and CD80 for M1 and CD68 and CD206 for M2 (Figure 11D).
Due to the Iloprost administration in the fracture zone, a
simultaneous significant decrease of pro-inflammatory M1 and
significant increase of anti-inflammatory and pro-regenerative
M2 macrophages was detectable. In order to evaluate if Iloprost
administration has an impact on bone resorption, osteoclasts
were also investigated by IHC. Osteoclasts were identified
by the myeloid-lineage marker CD68, the collagen digesting
enzyme cathepsinK (CTSK) and presence of multiple nuclei
(Figure 11E). No significant differences were observed in both
groups 3 days post-osteotomy.
Summarizing the data from the proof of concept study in
our in vivomouse osteotomy model system, the pro-regenerative
effect of Iloprost in bone healing was confirmed. We further
revealed underlying changes in the immune cell composition
in and around the fracture zone in the early inflammatory
phase toward a reduced pro-inflammatory and increased anti-
inflammatory cell phenotype caused by the application of
Iloprost. Thus, Iloprost is a promising agent to improve bone
regeneration by the downregulation of partial unfavorable pro-
inflammatory and a simultaneous support of anti-inflammatory
and pro-regenerative mediators.
DISCUSSION
Healing is impaired if a prolonged (pro-) inflammatory
phase persists and an early anti-inflammatory stimulus is
required. Thus, developing strategies that would ensure or
even enhance anti-inflammatory stimuli appears mandatory.
Iloprost is a well-known drug to treat diseases of the
vascular system like pulmonary arterial hypertension and
scleroderma (25, 29, 30). Its main function is conducted
via vasodilatation (widening of blood vessels). Regarding the
bone system, Iloprost is already successfully used to treat
bone marrow oedema, partially also in the context of bone
injuries (23, 24).
In the here presented study, the immune modulatory effect
of the synthetic prostacyclin analog Iloprost was evaluated for
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FIGURE 10 | Histological analysis of in vivo experiments in mouse osteotomies at days 3 and 21 post-osteotomy. (A) Representative Movat’s pentachrome pictures
are displayed for the respective time point and group. (B–E) Histomorphometrical analysis of the Movat Pentachrome stainings: (B) bone marrow, (C) cartilage tissue,
(D) connective tissue, and (E) mineralized bone tissue. Color coding of the Movat Pentachrome staining: mineralized bone = yellow, cartilage = dark blue-green,
connective tissue = light blue-green, muscle fibers = light orange, cell nuclei = purple, fibrin clot = red/orange. Scale bars equal 500µm, n = 6.
bone fracture healing. The impact of Iloprost was investigated
on immune cells and MSCs in vitro as well as in a well-
established mouse osteotomy model in vivo. We demonstrated
that the supplementation of Iloprost led to a decrease in
the expression of pro-inflammatory cytokines by immune
cells (T cells and macrophages) and thus promoted a shift
in the function of these cells toward the anti-inflammatory
path. The metabolic activity of the stimulated immune cells
was also downregulated by Iloprost further supporting the
observed decrease of the secreted pro-inflammatory cytokine
profile. Iloprost had no negative effect on the osteogenic
as well as chondrogenic function of MSCs. In an in vivo
proof of concept approach, the pro-regenerative capacity
of Iloprost as potential agent to further bone regeneration
was confirmed, evaluated by an improved healing outcome
after 21 days. Immunohistochemical analysis of the cellular
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FIGURE 11 | Immunohistochemical (IHC) analysis of the distribution of immune cells in the fracture zone 3 days post-osteotomy. (A) A section of a fractured femur
from the Iloprost treated group is displayed, Movat Pentachrome staining. The region of interest (ROI) for the quantitative analysis of IHC images is enlarged (red
rectangle). The black rectangle represents the region from which the representative examples of the respective IHC staining for (B) CD4+ and CD8+ T cells and
osteoblasts, (C) IFNγ producing CD8+ T cells; CD8+IFNγ+ cells = white indicator, (D) macrophages; M1-type macrophages = white indicator; M2-type
macrophages = yellow indicator, and (E) osteoclasts were taken. The quantification of the cellular distributions are displayed in the corresponding dot plot graphs.
Color code: Movat Pentachrome mineralized bone = yellow, cartilage = dark blue-green, connective tissue = light blue-green, muscle fibers = light orange, cell nuclei
= purple, fibrin clot = red/orange; (B) osteoblasts = white, CD8+ T cells = red, CD4+ T cells = green and cell nuclei = blue; (C) osteoblasts = white, CD8+ T cells
= red, IFNγ = green, cell nuclei = blue; (D) CD68 = green, CD80 = white, CD206 = red; (E) osteoclasts: double positive for cathepsinK = white and CD68 = green
cell nuclei = blue. Scale bars: 20µm (IHC) 1,000µm (Movat Pentachrome); n = 6.
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distribution in the fracture gap revealed a decrease of potential
unfavorable IFNγ producing CD8+ cells as well as an increase
of anti-inflammatory M2 macrophages in comparison to
the control group due to Iloprost administration concurring
with the in vitro results. Both are furthering the pro-
regenerative pathway.
The signaling receptor for prostacyclin and thus also for
Iloprost is found on a variety of different cell types, among
others on cells of the innate as well as adaptive immunity.
Iloprost signaling leads to an intracellular increase of cyclic
adenosine monophosphate (cAMP) via the stimulation of the
adenylyl cyclase. cAMP is an anti-inflammatory acting agent
that suppresses the effector function of CD4+ and CD8+
T cells (31, 32). Here, we also observed a decrease of the
secretion of the pro-inflammatory cytokines TNFα and IFNγ
from whole bone marrow cells as well as (IFNγ producing)
CD8+ T cells in vitro and in vivo under the presence of Iloprost.
This observation demonstrates the immune modulatory effect
of Iloprost on cellular components of the adaptive immunity
toward a reduced pro-inflammatory and thus pro-regenerative
phenotype. This finding was further confirmed by the increase of
the pro-regenerative M2 type macrophages under the influence
of Iloprost. The group of Alkhabit also showed an immune
modulatory effect of Iloprost on macrophage polarization toward
a pro-regenerative phenotype in an in vivo model system in
rats, supporting our findings (33). Regarding bone fracture
healing, possible negative effects of Iloprost on MSCs and bone
forming osteoblasts as well as bone resorbing osteoclasts have
to be considered. No possible negative effects by Iloprost on the
osteogenic and chondrogenic capacities of MSCs were observed
in vitro, further supporting the local application of Iloprost for
bone healing scenarios in vivo. In a proof of concept approach,
we evaluated the administration of Iloprost in amouse osteotomy
model system. Iloprost was inserted into a fibrin clot delivery
system, from which the prostacyclin analog was successively
released, which was shown by a downregulation of a pro-
inflammatory cellular distribution around the fracture gap 3 days
post osteotomy. The in vivo study confirmed the positive effect
of Iloprost on bone regeneration. Animals treated with Iloprost
showed a significantly improved bone healing outcome 21 days
post-osteotomy compared to untreated control mice evaluated
by µCT as well as histomorphometry after Movat’s Pentachrome
staining. The observed significantly enhanced bone formation
in the Iloprost treated animals can be explained by an earlier
starting of the regenerative process due to the down-regulated
pro-inflammatory phase at the beginning of the healing cascade
in comparison to the PBS treated control mice. Analysis of
the cellular distribution of specific immune cells 3 days post-
osteotomy in the fractured bones showed a clear tendency toward
a reduced pro-inflammatory and increased anti-inflammatory
cellular phenotype and cytokine secretion profile, as already
observed in the preceding in vitro study. Furthermore, no effect
on the relative amount of osteoblasts and osteoclasts in and
around the fracture gap were detectable after Iloprost treatment
3 days post-osteotomy in vivo. In vitro, we also showed that
the secreted cytokine milieu of activated and either Iloprost or
untreated T cells has a significant impact on the osteogenic
capacity of MSCs cultured in osteoinductive media. Our results
showed a compensatory effect by the Iloprost treatment on the
potential anti-regenerative cytokinemilieu produced by activated
T cells. Thus, the pro-regenerative effect of Iloprost is indirectly
mediated on MSCs/osteoblasts by changes in the functionality
of (pro-inflammatory) effector T cells participating in the bone
regeneration cascade. Next to the effect of Iloprost on CD8+
T cells and macrophages, an influence on other immune cell
could further impact bone healing in vivo. The early fracture
healing phase is characterized by an infiltration of cells of the
innate immunity like mast cells and neutrophils. For both,
it was already shown, that the administration of prostacyclin
analogs led to a reduced recruitment of these cells to the
site of injury (34–36). Furthermore, an inhibitory function of
Iloprost is reported for the secretion of effector cytokines of bone
marrow dendritic cells as well as Th1 and Th2 CD4+ T cells in
vitro (37). Thus, Iloprost is not only affecting the CD8+, but
also the CD4+ T cell compartment in diminishing the (pro-
inflammatory) effector cytokine secretion and thus function.
One major key element of the potential of Iloprost to improve
bone regeneration seems to be the time point of administration
during the healing scenario. The group of Dogan reported an
inhibitory effect of Iloprost on fracture repair in rats (38). There,
Iloprost was administered by a daily injection for 5 days, starting
at the time point of surgery. Due to the immune modulatory
effect of Iloprost, a too early application of the drug could lead
to an inhibition of the indispensable early pro-inflammatory
phase initiating the healing cascade. This hypothesis is further
supported by the reported effects of Iloprost on mast cells
and neutrophils. Both cell types are indispensable for the early
fracture healing phase to initiate the healing cascade. If Iloprost
is administered directly at the time point of surgery/injury, it
will inhibit the crucial recruitment of both cells types and will
therefore disturbed the formation of the necessary cellular and
cytokine milieu for a correct progression of the regeneration
cascade (35, 36). Therefore, we used a fibrin clot for a (1)
delayed and (2) successive release of Iloprost into the fracture
gap thereby allowing the first pro-inflammatory phase to proceed.
The positive impact of Iloprost in bone healing was already
demonstrated in a small case study in the clinic for the treatment
of subchondral stress fractures of the knee. Patients receiving
Iloprost showed an improved healing of the stress fractures in
comparison to the control group receiving the opioid analgesic
Tramadol (39). Even though Iloprost is beneficial for bone
healing applied systemically, this also bears considerable risks
which would be circumvented by a local application as we proved
in our proof of concept in vivo study. Thus, also in the treatment
of patients, the possible pro-regenerative effect of Iloprost in bone
healing was confirmed further supporting our in vivo and in
vitro results.
CONCLUSION
In the here presented study, the anti-inflammatory impact of
Iloprost was confirmed. Cellular components of the immune
system play a key role in bone fracture healing. An overwhelming
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pro-inflammatory phase in the early fracture healing cascade
is correlated with an impaired healing outcome (15). We
demonstrated that Iloprost has the potential to compensate the
partial unfavorable pro-inflammatory effect of effector T cells and
is able to stimulate the formation of an anti-inflammatory and
pro-regenerative cellular milieu improving fracture healing. In
a consecutive step, this strategy has to be confirmed in clinical
phase I/II trials.
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